New antiviral pill aims to shorten RSV symptoms in vulnerable adults

NCT ID NCT07658534

Recruiting now Disease control Sponsor: Shanghai Ark Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an oral antiviral called ziresovir (AK0529) in adults at high risk for severe RSV infection, such as those with chronic lung or heart disease, weakened immune systems, or age 65 and older. Participants receive either the drug or a placebo, and researchers measure how quickly lower respiratory symptoms like cough, wheezing, and shortness of breath improve. The goal is to see if ziresovir can speed recovery and reduce the burden of RSV in this vulnerable group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ziresovir (AK0529)
What this could lead to: If it works, this could provide a treatment to reduce severe RSV symptoms in vulnerable adults, potentially preventing hospitalizations.
What could go wrong: This is a mid-stage trial with 290 participants, so results may not confirm effectiveness. The drug may cause side effects or fail to outperform placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart disorder respiratory syncytial virus infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

Contacts and locations

Locations

Cangzhou Hospital of Integrated TCM-WM
RECRUITING

Cangzhou, Hebei, China
China-Japan Friendship Hospital
RECRUITING

Beijing, Beijing Municipality, China
Guangzhou Medical University Panyu Central Hospital
NOT_YET_RECRUITING

Guangzhou, Guangdong, China
Henan Infectious Disease Hospital (The Sixth People's Hospital of Zhengzhou)
NOT_YET_RECRUITING

Zhengzhou, Henan, China
People's Hospital of Rui'an City
RECRUITING

Rui’an, Zhejiang, China
Taizhou Hospital of Zhejiang Province
RECRUITING

Taizhou, Zhejiang, China
The First Affiliated Hospital of Nanyang Medical College
RECRUITING

Nanyang, Henan, China
Wuhan Sixth Hospital
RECRUITING

Wuhan, Hubei, China
Zhejiang Hospital
NOT_YET_RECRUITING

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.